Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03066726 · ClinicalTrials.gov registry record
Does the Cerebroplacental Ratio (CPR) Predict Adverse Outcomes in Low Risk Pregnancies?
A clinical trial, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- 580
- Enrollment target
NCT03066726: Clinical Trial study, sponsored by Rutgers, The State University of New Jersey.
NCT03066726 is a clinical trial that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 580 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03066726 was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- 580 participants
- Enrollment target
Study Summary
Ultrasound Doppler studies are used during pregnancy to help manage pregnancies complicated by fetal growth restriction. The cerebroplacental ratio may predict adverse outcomes in low risk pregnancies. In a prospective study, the investigators will examine whether fetuses with an abnormal CPR at or near term are at increased risk for being delivered by cesarean,
Primary Outcome
Cesarean delivery rate for non reassuring fetal heart tracings
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2020-05-07 |
Why NCT03066726 stopped before completion
NCT03066726 is an observational study that tracks outcomes without assigning an intervention. The registered 580 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03066726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03066726 about?
NCT03066726 is a clinical study titled "Does the Cerebroplacental Ratio (CPR) Predict Adverse Outcomes in Low Risk Pregnancies?". Ultrasound Doppler studies are used during pregnancy to help manage pregnancies complicated by fetal growth restriction. The cerebroplacental ratio may predict adverse outcomes in low risk pregnancies. In a prospective study, the investigators will examine whether fetuses with an abnormal CPR at or ...
What is the current status of trial NCT03066726?
This trial is currently terminated. The enrollment target is 580 participants. The study started on 2017-05-15. Estimated completion is 2020-05-07.
Who is sponsoring clinical trial NCT03066726?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- NCT05143177 · 580 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
- NCT05696353 · 580 participants · Phase 3
Teen Driving Translation Study (NIH)
- NCT06578104 · 580 participants
PULSED AF Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI